Literature DB >> 34787322

A population-based study of scoliosis among males diagnosed with a dystrophinopathy identified by the Muscular Dystrophy Surveillance, Tracking, and Research Network (MD STARnet).

Kristin M Conway1, Amber Gedlinske2, Katherine D Mathews3, Seth Perlman4, Nicholas Johnson5, Russell Butterfield6, Man Hung7, Jerry Bounsanga8, Dennis Matthews9, Joyce Oleszek9, Paul A Romitti1.   

Abstract

INTRODUCTION/AIMS: Scoliosis is a common comorbidity among individuals diagnosed with a dystrophinopathy. We examined associations between clinical predictors and scoliosis in childhood-onset dystrophinopathy.
METHODS: The progression and treatment of scoliosis were obtained from data collected by the US population-based Muscular Dystrophy Surveillance, Tracking, and Research Network. Associations between loss of independent ambulation (LoA) and corticosteroid use and scoliosis outcomes (ages at or exceeding Cobb angle thresholds [10°, 20°, 30°]; surgery) were estimated using Kaplan-Meier curve estimation and extended Cox regression modeling.
RESULTS: We analyzed curvature data for 513 of 1054 individuals ascertained. Overall, approximately one-half had at least one radiograph and one-quarter had a curvature of at least 20°. The average maximum curvature was 25.0° (SD = 21.5°) among all individuals and 42.8° (SD = 18.8°) among those recommended for surgery. Higher adjusted hazards ratio of curvature (aHR(curvature) [95% confidence interval]) were found among individuals with LoA compared to those without LoA (aHR(10)  = 6.2 [4.4, 8.7], aHR(20)  = 15.3 [7.4, 31.7], aHR(30)  = 31.6 [7.7, 128.9]), among individuals who did not use corticosteroids compared to those who did (aHR(10)  = 1.2 [0.9, 1.7], aHR(20)  = 1.8 [1.1, 2.7], aHR(30)  = 2.3 [1.3, 4.0]), and among non-ambulatory individuals who used corticosteroids after LoA compared to those who did not (aHR(10)  = 1.8 [1.2, 2.8], aHR(20)  = 1.6 [1.0, 2.6], aHR(30)  = 3.6 [1.6, 7.9]). Scoliosis surgery among individuals with LoA who did not use corticosteroids was more than double compared to those who used (aHR = 2.3 [1.3, 4.2]). DISCUSSION: Our retrospective observational study suggests corticosteroids may delay spinal curvature progression and need for scoliosis surgery. Continuing corticosteroids after LoA also showed potential benefits of delaying curvature progression, additional studies are needed to confirm this finding or address the magnitude of benefit.
© 2021 Wiley Periodicals LLC.

Entities:  

Keywords:  Duchenne muscular dystrophy; corticosteroid; dystrophinopathy; scoliosis

Mesh:

Substances:

Year:  2021        PMID: 34787322      PMCID: PMC8752499          DOI: 10.1002/mus.27464

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.852


  43 in total

Review 1.  A practical guide to understanding Kaplan-Meier curves.

Authors:  Jason T Rich; J Gail Neely; Randal C Paniello; Courtney C J Voelker; Brian Nussenbaum; Eric W Wang
Journal:  Otolaryngol Head Neck Surg       Date:  2010-09       Impact factor: 3.497

2.  Impact of a Comparative Study on the Management of Scoliosis in Duchenne Muscular Dystrophy: Are Corticosteroids Decreasing the Rate of Scoliosis Surgery in the United States?

Authors:  Brandon L Raudenbush; Caroline P Thirukumaran; Yue Li; James O Sanders; Paul T Rubery; Addisu Mesfin
Journal:  Spine (Phila Pa 1976)       Date:  2016-09       Impact factor: 3.468

3.  Muscular Dystrophy Surveillance Tracking and Research Network (MD STARnet): case definition in surveillance for childhood-onset Duchenne/Becker muscular dystrophy.

Authors:  Katherine D Mathews; Chris Cunniff; Jiji R Kantamneni; Emma Ciafaloni; Timothy Miller; Dennis Matthews; Valerie Cwik; Charlotte Druschel; Lisa Miller; F John Meaney; John Sladky; Paul A Romitti
Journal:  J Child Neurol       Date:  2010-09       Impact factor: 1.987

4.  Prednisone in Duchenne muscular dystrophy.

Authors:  D B Drachman; K V Toyka; E Myer
Journal:  Lancet       Date:  1974-12-14       Impact factor: 79.321

5.  The muscular Dystrophy Surveillance Tracking and Research Network (MD STARnet): surveillance methodology.

Authors:  Lisa A Miller; Paul A Romitti; Christopher Cunniff; Charlotte Druschel; Katherine D Mathews; F John Meaney; Dennis Matthews; Jiji Kantamneni; Zhen-Fang Feng; Nancy Zemblidge; Timothy M Miller; Jennifer Andrews; Deborah Fox; Emma Ciafaloni; Shree Pandya; April Montgomery; Aileen Kenneson
Journal:  Birth Defects Res A Clin Mol Teratol       Date:  2006-11

6.  The Canadian experience with long-term deflazacort treatment in Duchenne muscular dystrophy.

Authors:  Laura C McAdam; Amanda L Mayo; Benjamin A Alman; W Douglas Biggar
Journal:  Acta Myol       Date:  2012-05

7.  Prednisolone therapy in Duchenne muscular dystrophy prolongs ambulation and prevents scoliosis.

Authors:  O Yilmaz; A Karaduman; H Topaloğlu
Journal:  Eur J Neurol       Date:  2004-08       Impact factor: 6.089

8.  Effect of spinal surgery on lung function in Duchenne muscular dystrophy.

Authors:  J D Kennedy; A J Staples; P D Brook; D W Parsons; A D Sutherland; A J Martin; L M Stern; B K Foster
Journal:  Thorax       Date:  1995-11       Impact factor: 9.139

9.  Scoliosis management in Duchenne muscular dystrophy: prospective study of modified Jewett hyperextension brace.

Authors:  A P Colbert; C Craig
Journal:  Arch Phys Med Rehabil       Date:  1987-05       Impact factor: 3.966

10.  Glucocorticoid treatment for the prevention of scoliosis in children with Duchenne muscular dystrophy: long-term follow-up.

Authors:  David E Lebel; John A Corston; Laura C McAdam; W Douglas Biggar; Benjamin A Alman
Journal:  J Bone Joint Surg Am       Date:  2013-06-19       Impact factor: 5.284

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.